ALIAmides
Astrocytes colture. © Epitech Group SpA
Research and development
Through intuition and ongoing scientific research, we continue to explore new avenues in pharmacology to improve health and quality of life “as nature intended”.
Since the 1990s, we have enthusiastically and consistently made substantial investments in R&D, driven by our ultimate commitment to ethical innovation.
Naturally selected actions improving health conditions exist already: our mission is to follow them.
Francesco della Valle – Founder of Epitech Group
years of research into the use of micro-PEA
Ongoing research projects
Scientific evidence on the effectiveness of micro-PEA and ultramicrocomposites in neuroinflammatory disorders
ALIAmide molecules
Epitech Group is leading cutting-edge research into ALIAmides and PEA. This research originated in Italy and was the scientific brainchild of Rita Levi-Montalcini, winner of the Nobel Prize for Medicine. Working closely with the Nobel Prize winner, we spearheaded the research development and made it our main focus.
Resting microglia (green), in spinal cord.
Courtesy of Livio Luongo.
© Epitech Group
Mast cell on blood vessel.
Realised by our Laboratories.
© Epitech Group
The patented PEA micronisation technique
After over 10 years of research into the chemical and physical characteristics of PEA and the best pharmaceutical technique for administering it, we have secured several patents covering the synthesis and micronisation of the PEA molecule.
Micro-PEA demonstrates superior bioactivity, meaning it works more effectively in the body. It has an effective modulatory effect on the non-neuronal cells (mast cells, microglia and astrocytes) responsible for peripheral and central neuroinflammation.
Resting microglia (green), in spinal cord.
Courtesy of Livio Luongo.
© Epitech Group
Continuous evolution
Approximately 400 international patents are the result of the Group’s research and its application across a variety of medical and pharmacological research fields. This is a testament to our vocation for cutting-edge pharmacology.
This is a testament to our vocation for cutting-edge pharmacology. As our expertise grows, we aim to promote a pharmaceutical approach that rebalances normal biological processes, rather than counteracting pathological ones. In doing so, we hope to make a considerable contribution to the sector’s evolution.
Continuous evolution
Approximately 400 international patents are the result of the Group’s research and its application across a variety of medical and pharmacological research fields. This is a testament to our vocation for cutting-edge pharmacology.
This is a testament to our vocation for cutting-edge pharmacology. As our expertise grows, we aim to promote a pharmaceutical approach that rebalances normal biological processes, rather than counteracting pathological ones. In doing so, we hope to make a considerable contribution to the sector’s evolution.
